Brain-Computer Interface Company Synchron Secures $200M Funding
Synchron, a New York-based company specializing in non-surgical brain-computer interface (BCI) technology, has raised $200 million in a Series D funding round. This investment aims to speed up the commercialization of its first-generation Stentrode BCI platform and support the development of a new, advanced interface.
Funding Details and Investors
This latest round increases Synchron’s total funding to $345 million. Double Point Ventures led the investment, joined by existing backers ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New participants include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
About the Stentrode BCI Platform
The Stentrode is the first endovascular brain-computer interface designed to convert brain activity into digital commands without the need for open-brain surgery. It is implanted through a minimally invasive catheter procedure, positioning the device within blood vessels to interface with the motor cortex. This setup enables wireless recording and transmission of neural signals, allowing users to control digital devices hands-free.
Synchron describes the Stentrode as "the first endovascular brain-computer interface, designed to translate brain activity into digital commands without open-brain surgery."
Summary
Synchron's successful fundraising marks a major milestone toward making its innovative, minimally invasive brain-computer interface widely available and advancing cutting-edge neurotechnology.